FDA approves new use for Celgene's cancer drug Revlimid

February 18, 2015 4:05 PM

17 0

WASHINGTON (Reuters) - The U.S. Food and Drug Administration has expanded the authorized use of Celgene Corp's cancer drug Revlimid to include newly diagnosed patients with multiple myeloma, the company said on Wednesday.

Previously the drug was only approved for patients who had received at least one previous therapy. Physicians in the United States have long been prescribing Revlimid for new patients on an "off-label" basis, but the company had not been allowed to promote its use in this population.

Read more

To category page